| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,845 | 3,955 | 13:50 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.10. | Vimian Q3 2026 slides: 15% revenue growth, strong cash generation | 4 | Investing.com | ||
| VIMIAN GROUP Aktie jetzt für 0€ handeln | |||||
| 22.10. | Vimian steigert Q3-Umsatz um 15 % - Aktie legt vorbörslich um 2,1 % zu | - | Investing.com Deutsch | ||
| 22.10. | Vimian Group verzeichnet im dritten Quartal 11 % organisches Wachstum | 1 | Investing.com Deutsch | ||
| 22.10. | Vimian Group AB: Vimian's Interim Report for the third quarter of 2026 | 364 | GlobeNewswire (Europe) | Continued strong performance
Revenue increased by 15 per cent to EUR 120.3m (104.3) with organic growth of 11 per centAdjusted EBITA increased 14 per cent to EUR 29.2m (25.5) corresponding to a margin... ► Artikel lesen | |
| 21.10. | Vimian Group AB: Vimian expands its surgical offering through the acquisition of Norfolk Medical Products | 232 | GlobeNewswire (Europe) | Vimian Group AB (publ) has signed an agreement to acquire Norfolk Medical Products, Inc. ("Norfolk"), a leading niche provider of implants and consumables for veterinary soft tissue surgery in the US.... ► Artikel lesen | |
| 14.09. | Vimian Group AB: Change to the Vimian Group AB (publ) management team and appointment of new Head of M&A | 511 | GlobeNewswire (Europe) | Vimian Group AB (publ) ("Vimian") appoints Andrea Tidholm as new Head of M&A, reporting to CFO Carl-Johan Zetterberg Boudrie, effective 5 October. Andrea Tidholm has twenty years of M&A experience and... ► Artikel lesen | |
| 27.08. | Vimian Group AB: Vimian Group AB (publ) appoints Hans Lord Skarplöth as Head of Specialty Pharma and member of the Vimian Group management team | 249 | GlobeNewswire (Europe) | Vimian Group AB (publ) ("Vimian") appoints Hans Lord Skarplöth as Head of Specialty Pharma and member of the Vimian Group Management Team, effective 1 October. Hans brings proven CEO experience, strong... ► Artikel lesen | |
| 17.07. | Vimian Group AB Q2 Sales Increase | 1 | RTTNews | ||
| 17.07. | Vimian Group AB: Vimian's Interim Report for the second quarter of 2026 | 477 | GlobeNewswire (Europe) | A strong quarter
Revenue increased by 17 per cent to EUR 121.6m (104.3) with organic growth of 12 per centAdjusted EBITA increased 17 per cent to EUR 29.7m (25.4) corresponding to a margin of 24.5 per... ► Artikel lesen | |
| 18.06. | Vimian Group AB: Subscription period for Vimian's incentive program 2023-2026 has commenced | 265 | GlobeNewswire (Europe) | Vimian Group AB (publ) ("Vimian") announces that the subscription period for Vimian's incentive program 2023-2026, a warrant program for employees in the group ("LTI 2023") commenced on 15 June 2026... ► Artikel lesen | |
| 29.04. | Vimian Group AB: Press release from the Annual General Meeting in Vimian Group AB (publ) on 29 April 2026 | 355 | GlobeNewswire (Europe) | Vimian held its Annual General Meeting today 29 April 2026. The Annual General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights... ► Artikel lesen | |
| 29.04. | Vimian Group AB: Vimian's Interim Report for the first quarter of 2026 | 314 | GlobeNewswire (Europe) | Positive start to the year
Revenue increased by 8 per cent to EUR 116.0m (107.5) with organic growth of 9 per centAdjusted EBITA increased 3 per cent to EUR 29.2m (28.3) corresponding to a margin of... ► Artikel lesen | |
| 13.03. | Vimian Group AB: Vimian Group AB (publ) appoints Lotta Lundaas Head of Medtech and member of the Vimian Group management team | 355 | GlobeNewswire (Europe) | Vimian Group AB (publ) ("Vimian") appoints Lotta Lundaas Head of MedTech and member of the Vimian Group management team, effective 13 April. Lotta Lundaas brings significant experience from scaling... ► Artikel lesen | |
| 12.02. | Vimian Group AB: Vimian's year-end report for 2025 | 533 | GlobeNewswire (Europe) | Solid finish to 2025
Net revenue increased by 4 per cent to EUR 109.0m (104.9) with organic growth of 6 per centAdjusted EBITA increased 6 per cent to EUR 26.1m (24.6) corresponding to a margin of 24.0... ► Artikel lesen | |
| 12.01. | Vimian Group AB: Vimian Group AB (publ) announces departure of Head of Specialty Pharma segment | 450 | GlobeNewswire (Europe) | Vimian Group AB (publ) ("Vimian") announces that Magnus Kjellberg has decided to step down from the group management team and his position as Head of Vimian's Specialty Pharma segment during spring... ► Artikel lesen | |
| 23.12.25 | Vimian Group AB: Vimian acquires I-Vet to strengthen its companion animal diagnostics offering | 792 | GlobeNewswire (Europe) | Vimian Group AB (publ) has signed an agreement to acquire I-Vet, one of the leading providers of companion animal diagnostics in Italy, with annual revenues of around EUR 5.6 million.
I-Vet was founded... ► Artikel lesen | |
| 24.11.25 | Vimian Group AB: Vimian Group AB (publ) appoints Alireza Tajbakhsh as CEO | 379 | GlobeNewswire (Europe) | Vimian Group AB (publ) ("Vimian") appoints Alireza Tajbakhsh as Chief Executive Officer, effective today. Alireza Tajbakhsh joined Vimian in 2021 and is currently Head of the Veterinary Services segment... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 54,13 | +0,71 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius kündigt Verkauf von rund 13,4 Millionen Aktien der Fresenius Medical Care AG an - Finanzbeteiligung soll auf rund 20 Prozent sinken | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Sonstiges
Fresenius kündigt Verkauf von rund 13,4 Millionen Aktien der Fresenius Medical Care AG an - Finanzbeteiligung soll... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,370 | -0,86 % | Aktien Frankfurt: Etwas stabilisiert - Tech-Werte profitieren von Nvidia-Bericht | FRANKFURT (dpa-AFX) - Der beruhigende Quartalsbericht des KI-Riesen Nvidia hat den zuletzt schwachen Dax am Mittwoch etwas stabilisiert. Der deutsche Leitindex lag am Mittag mit 0,2 Prozent im Plus... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 43,530 | +0,53 % | DEUTSCHE BANK RESEARCH stuft Siemens Healthineers auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Siemens Healthineers nach Zahlen zum vierten Geschäftsquartal 2025/26 von 39 auf 43 Euro angehoben, aber die Einstufung auf... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 33,440 | -2,79 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Underweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 27 auf 26 Euro gekappt und die Aktien von "Equal Weight" auf "Underweight" abgestuft. Dem... ► Artikel lesen | |
| ECKERT & ZIEGLER | 15,110 | +1,61 % | EQS-News: Eckert & Ziegler SE: Bereinigtes EBIT im dritten Quartal +25%. Prognose 2026 bestätigt | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): 9-Monatszahlen
Eckert & Ziegler: Bereinigtes EBIT im dritten Quartal +25%. Prognose 2026 bestätigt
12.11.2026 / 07:45 CET/CEST
Für... ► Artikel lesen | |
| INTUITIVE SURGICAL | 391,95 | +0,20 % | BMO bekräftigt Einstufung für Intuitive Surgical angesichts des Wachstumspotenzials bei ambulanten OP-Zentren | ||
| UNITEDHEALTH | 353,20 | -0,28 % | UnitedHealthcare partners with pharmacies to expand care access | ||
| DRAEGERWERK | 119,20 | 0,00 % | BERENBERG stuft Draegerwerk auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Bewertung von Drägerwerk beim Kursziel von 156 Euro mit "Buy" aufgenommen. Beim Medizin- und Sicherheitstechnik winke ein massiver Profitabilitätsschub... ► Artikel lesen | |
| MEDTRONIC | 91,68 | -1,40 % | Medtronic: What Happens When Healthcare Technology Starts With People | From living rooms to operating rooms, human-centered design is informing the future of tech?Key takeawaysHuman-centered design at Medtronic uses patient, caregiver, and clinician insights to make medical... ► Artikel lesen | |
| GERRESHEIMER | 32,800 | +2,56 % | Gerresheimer: Jetzt muss das Schlussquartal liefern | ||
| THERMO FISHER | 627,60 | +0,51 % | 65% der untersuchten FDA-Rückschläge betrafen Produktionsstätten: Die unsichtbare Hürde für Lonza, Thermo Fisher und NeuroThera | ||
| TELADOC HEALTH | 7,744 | +0,31 % | Teladoc Launches Employer Contribution Option for GLP-1s | ||
| STRATEC | 28,050 | +3,70 % | EQS-News: STRATEC SE: STRATEC berichtet finale Zahlen für die ersten neun Monate 2026 | EQS-News: STRATEC SE
/ Schlagwort(e): Quartalsergebnis
STRATEC BERICHTET FINALE ZAHLEN FÜR DIE ERSTEN NEUN MONATE 2026
12.11.2026 / 06:55 CET/CEST
Für... ► Artikel lesen | |
| RHOEN-KLINIKUM | 14,400 | -2,04 % | Klinik für Anästhesiologie und Intensivmedizin am RHÖN-KLINIKUM Campus Bad Neustadt unter neuer Leitung | Bad Neustadt a.d. Saale (ots) - Dr. Stefan Reisch übernimmt Chefarztposition - langjähriger Mitarbeiter am Standort Bad NeustadtDie Klinik für Anästhesiologie und Intensivmedizin am RHÖN-KLINIKUM Campus... ► Artikel lesen | |
| ESSILORLUXOTTICA | 181,45 | +2,46 % | 1,8 Milliarden Menschen mit Alterssichtigkeit: Warum Alcon und EssilorLuxottica neue Sehlösungen entwickeln |